{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:14:44Z","timestamp":1774530884602,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.revmed.2009.05.016","type":"journal-article","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T04:58:51Z","timestamp":1274504331000},"page":"615-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Le lymphome \u00e0 cellules du manteau\u00a0: du diagnostic aux perspectives th\u00e9rapeutiques"],"prefix":"10.1016","volume":"31","author":[{"given":"S.","family":"Le Gouill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2009.05.016_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V78.2.259.bloodjournal782259","article-title":"Bcl-1, t(11;14), and mantle cell-derived lymphomas","volume":"78","author":"Raffeld","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma A proposal for unification of morphologic, immunologic, and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.revmed.2009.05.016_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood.V84.2.403.403","article-title":"Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle","volume":"84","author":"Hummel","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib4","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80\u00a0cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib5","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992\u00a0and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2009.05.016_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.V76.7.1387.1387","article-title":"Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11\u00a0bcl-1\u00a0locus","volume":"76","author":"Williams","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.revmed.2009.05.016_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2009.05.016_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2006-01-0015","article-title":"A chromosomal translocation in cyclin D1-negative\/cyclin D2-positive mantle cell lymphoma fuses the CCND2\u00a0gene to the IGK locus","volume":"108","author":"Gesk","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2009.05.016_bib13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2009.05.016_bib14","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib16","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2009.05.016_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2009.05.016_bib18","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib19","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2009.05.016_bib20","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib21","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2\u00a0multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib22","article-title":"RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA","author":"Delarue","year":"2008","journal-title":"Congr\u00e8s ASH"},{"key":"10.1016\/j.revmed.2009.05.016_bib23","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib25","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib26","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib27","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.revmed.2009.05.016_bib28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.revmed.2009.05.016_bib29","first-page":"1580","article-title":"High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma","volume":"90","author":"Vigouroux","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2009.05.016_bib30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","article-title":"Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"104","author":"Thieblemont","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2009.05.016_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib32","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2009.05.016_bib33","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib34","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib35","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib37","doi-asserted-by":"crossref","unstructured":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"key":"10.1016\/j.revmed.2009.05.016_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","article-title":"Ki-67\u00a0expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma","volume":"69","author":"Raty","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2009.05.016_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V95.2.619","article-title":"Increased proteasome degradation of cyclin-dependent kinase inhibitor p27\u00a0is associated with a decreased overall survival in mantle cell lymphoma","volume":"95","author":"Chiarle","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib40","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67\u00a0proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib41","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2006.08.7999","article-title":"Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors","volume":"25","author":"Kienle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib42","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53\u00a0mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.revmed.2009.05.016_bib44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2009.05.016_bib45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib46","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2009.05.016_bib47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/asheducation-2007.1.270","article-title":"Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways","volume":"2007","author":"O\u2019Connor","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.revmed.2009.05.016_bib48","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.hoc.2008.07.001","article-title":"Therapy of mantle cell lymphoma: current standards and future strategies","volume":"22","author":"Schmidt","year":"2008","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866310004741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866310004741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:26:22Z","timestamp":1759335982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866310004741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0248866310004741"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2009.05.016","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le lymphome \u00e0 cellules du manteau\u00a0: du diagnostic aux perspectives th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2009.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}